T-13-20: Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months' follow-up.

Details

Language :

English

ISSN :

07209355

Volume :

43

Database :

Complementary Index

Journal :

Hämostaseologie

Publication Type :

Academic Journal

Accession number :

162983758

Full Text :

https://doi.org/10.1055/s-0042-1760523